Hypolipidemic effects of Alismatis Rhizoma decoction on the lipid profile in hyperlipidemia rats by RNA-sequencing

doi:10.5246/jcps.2021.05.032

Abstract

Abstract:

As a disorder of lipid metabolism, hyperlipidemia (HLP) is characterized by elevated levels of lipids in the blood circulation. It is consistently related to the development of cardiovascular events and diseases associated with metabolic syndrome. Alismatis Rhizoma decoction (ARD), a well-known traditional Chinese medicine prescription, has long been used for treating vertigo, which is a symptom experienced by HLP patients. In this study, we aimed to investigate the hyperlipidemic activity and the potential molecular mechanisms of ARD in HLP rats at the transcriptional level. RNA sequencing and transcriptome analysis were performed collaboratively, including analysis of differentially expressed genes (DEGs), GO functions, and KEGG pathway analysis. The results showed that 1981 DEGs (1370 upregulated and 611 downregulated) were identified in the HFD group compared with the CON group. Moreover, 474 DEGs (350 upregulated and 124 downregulated) were detected in the ARD group compared with the HFD group. Furthermore, GO analysis revealed that DEGs were mainly involved in the following functions: developmental process, response to an external stimulus, ion transport, alcohol binding, and plasma membrane part. Pathway analysis suggested that these DEGs were significantly enriched in bile secretion, malaria, cell adhesion molecules, retinol metabolism, the sphingolipid signaling pathway, chemical carcinogenesis, and the T cell receptor signaling pathway. In conclusion, our study demonstrated that ARD alleviated the lipid metabolism disorder caused by HLP through multiple mechanisms, which provided vital scientific evidence for further pharmacological studies of ARD.

Key words: Alismatis Rhizoma decoction, Hyperlipidemia, RNA-sequencing, Lipid profile

Supporting:

Xiaomei Xu, Lisha Li, Yamin Zhang, Xuehua Lu, Rongqing Xu, Shuangshuang Wu, Wei Lin, Wenjin Lin. Hypolipidemic effects of Alismatis Rhizoma decoction on the lipid profile in hyperlipidemia rats by RNA-sequencing[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(5): 409-420.

Figures/Tables 6

References 35

[1]	Machaba, K.E.; Cobongela, S.Z.Z.; Mosa, R.A.; Oladipupo, L.A.; Djarova, T.G.; Opoku, A.R. In vivo anti-hyperlipidemic activity of the triterpene from the stem bark of Protorhus longifolia (Benrh) Engl. Lipids Health Dis. 2014, 13, 131.
[2]	Adisakwattana, J.M.; Srichairat, S.; Chanasit, C.; Tirapongporn, H.; Chanathong, B.; Ngamukote, S.; Mäkynen, K.; Sapwarobol, S. Lipid-Lowering mechanisms of grape seed extract (Vitisvinifera L) and its antihyperlipidemic activity. J. Med. Plant Res. 2010, 4, 2113–2120.
[3]	Jacobson, T.A.; Miller, M.; Schaefer, E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 2007, 29, 763–777.
[4]	Remick, J.; Weintraub, H.; Setton, R.; Offenbacher, J.; Fisher, E.; Schwartzbard, A. Fibrate therapy. Cardiol. Rev. 2008, 16, 129–141.
[5]	Cham, S.; Evans, M.A.; Denenberg, J.O.; Golomb, B.A. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010, 30, 541–553.
[6]	Dou, X.B.; Wo, X.D.; Fan, C.L. Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine. Chin. J. Integr. Med. 2008, 14, 71–75.
[7]	Liu, Z.L.; Liu, J.P.; Zhang, A.L.; Wu, Q.; Ruan, Y.; Lewith, G.; Visconte, D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst. Rev. 2010, doi.org/10.1002/14651858.CD008305.
[8]	Hu, X.F.; Cheng, Z.H.; Wang, S.D.; Fang, N.B.; Yu, S.G. Effects of Rhizoma Alismatis Decoction on Levels of Blood Lipids in Rats. Lishizhen Med. Mater. Med. Res. 2011, 22, 2073–2074.
[9]	Fang, J.; Sun, X.Q.; Xue, B.Y.; Fang, N.Y.; Zhou, M. Dahuang Zexie decoction protects against high-fat diet-induced NAFLD by modulating gut microbiota-mediated toll-like receptor 4 signaling activation and loss of intestinal barrier. Evid. Based Complement. Alternat. Med. 2017, 2017, 2945803.
[10]	Song, C.; Huang, X.; Lu, K.; Peng, M.; Yu, S.; Fang, N. The rationality of the hypolipidemic effect of alismatis rhizoma decoction, a classical chinese medicine formula in high-fat diet-induced hyperlipidemic mice. Iran J. Pharm. Res. 2014, 13, 641–649.
[11]	Wang, Z.; Gerstein, M.; Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10, 57–63.
[12]	Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010, 26, 139–140.
[13]	Zhang, J.X.; Wu, K.L.; Zeng, S.J.; Teixeira da Silva, J.A.; Zhao, X.L.; Tian, C.G.; Xia, H.Q.; Duan, J. Transcriptome analysis of Cymbidium sinense and its application to the identification of genes associated with floral development. BMC Genom. 2013, 14, 1–17.
[14]	Kanehisa, M.; Araki, M.; Goto, S.; Hattori, M.; Hirakawa, M.; Itoh, M.; Katayama, T.; Kawashima, S.; Okuda, S.; Tokimatsu, T.; Yamanishi, Y. KEGG for linking genomes to life and the environment. Nucl. Acids Res. 2007, 36, D480–D484.
[15]	Le, Z.Y. Study on the Mechanism for the Hypolipidemic Effect of Alismatics Rhizoma Detection. Doctoral thesis, 2012.
[16]	Gu, S.J.; Wu, J.; Liu, D.Y.; Liu, P.; Fang, N.B.; Yu, S.G. The Blood Pressure Regulated Effect of Zexie Decoction in Mice. Lishizhen Med. Mater. Med. Res. 2010, 21, 272–273.
[17]	Chen, X.X.; Zhao, X.M.; Wu, Y.; Su, Z.Y. Influence of Zexie Decoction with Different Ratios on Urinary Amount and Urine AQP2 of Water-loaded Rat: An Experimental Study. China Mod. Doctor. 2009, 47, 23–24.
[18]	Zhang, L.L.; Xu, W.; Xu, Y.L.; Chen, X.P.; Huang, M.Q.; Lu, J.J. Therapeutic potential of Rhizoma Alismatis: a review on ethnomedicinal application, phytochemistry, pharmacology, and toxicology. Ann. NY. Acad Sci. 2017, 1401, 90–101.
[19]	Tian, T.; Chen, H.; Zhao, Y.Y. Traditional uses, phytochemistry, pharmacology, toxicology and quality control of Alisma orientale (Sam.) Juzep: a review. J. Ethnopharmacol. 2014, 158, 373–387.
[20]	Shu, Z.H.; Pu, J.; Chen, L.; Zhang, Y.B.; Rahman, K.; Qin, L.P.; Zheng, C.J. Alisma orientale: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. Am. J. Chin. Med. 2016, 44, 227–251.
[21]	Ma, Q.J.; Han, L.; Bi, X.X.; Wang, X.B.; Mu, Y.; Guan, P.P.; Li, L.Y.; Huang, X.S. Structures and biological activities of the triterpenoids and sesquiterpenoids from Alisma orientale. Phytochemistry. 2016, 131, 150–157.
[22]	Zhu, B.; Zhang, Q.L.; Hua, J.W.; Cheng, W.L.; Qin, L.P. The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz.: a review. J. Ethnopharmacol. 2018, 226, 143–167.
[23]	Yang, E.; Zhong, Y.M.; Feng, Y.F. Advance on the chemical constituents and pharmacological effects of Atractylodes macrocephala Koidz. J. Guangdong Pharm. Univ. 2012, 28, 218–221.
[24]	Wang, X.T.; Li, L.H.; Ran, X.K.; Dou, D.Q.; Li, B.; Yang, B.Y.; Li, W.; Koike, K.; Kuang, H.X. What caused the changes in the usage of Atractylodis Macrocephalae Rhizoma from ancient to current times? J. Nat. Med. 2016, 70, 36–44.
[25]	Pedersen, T.R.; Tobert, J.A. Simvastatin: a review. Expert. Opin. Pharmacother. 2004, 5, 2583–2596.
[26]	Al-Rasheed, N.M.; Al-Rasheed, N.M.; Hasan, I.H.; Al-Amin, M.A.; Al-Ajmi, H.N.; Mohamad, R.A.; Mahmoud, A.M. Simvastatin ameliorates diabetic cardiomyopathy by attenuating oxidative stress and inflammation in rats. Oxid. Med. Cell Longev. 2017, 2017, 1092015.
[27]	Wolfe, A.D.; Arnold, D.B.; Chen, X.S. Comparison of RNA editing activity of APOBEC1-A1CF and APOBEC1-RBM47 complexes reconstituted in HEK293T cells. J. Mol. Biol. 2019, 431, 1506–1517.
[28]	Galloway, C.A.; Ashton, J.; Sparks, J.D.; Mooney, R.A.; Smith, H.C. Metabolic regulation of APOBEC-1 Complementation Factor trafficking in mouse models of obesity and its positive correlation with the expression of ApoB protein in hepatocytes. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2010, 1802, 976–985.
[29]	Hu, P.; Lu, L.; Hu, B.; Qin, Y.H. Recapture of hepatic apolipoprotein B mRNA editing may be a promising strategy to relieve nephrotic dyslipidemia. Med. Hypotheses. 2010, 75, 561–563.
[30]	Koonen, D.P.Y.; Jacobs, R.L.; Febbraio, M.; Young, M.E.; Soltys, C.L.M.; Ong, H.; Vance, D.E.; Dyck, J.R.B. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007, 56, 2863–2871.
[31]	Fabbrini, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology. 2010, 51, 679–689.
[32]	Vergani, L.; Lanza, C.; Borghi, C.; Scarabelli, L.; Panfoli, I.; Burlando, B.; Dondero, F.; Viarengo, A.; Gallo, G. Efects of growth hormone and cadmium on the transcription regulation of two metallothionein isoforms. Mol. Cell Endocrinol. 2007, 263, 29–37.
[33]	Cherian, M.G.; Kang, Y.J. Metallothionein and liver cell regeneration. Exp. Biol. Med. 2006, 231, 138–144.
[34]	Oliver, J.; Jiang, S.; Cherian, M. Augmented hepatic injury followed by impaired regeneration in metallothionein-I/II knockout mice after treatment with thioacetamide. Toxicol. Appl. Pharmacol. 2006, 210, 190–199.
[35]	Grasselli, E.; Canesi, L.; Voci, A.; De Matteis, R.; Demori, I.; Fugassa, E.; Vergani, L. Effects of 3,5-diiodo-L-thyronine administration on the liver of high fat diet-fed rats. Exp. Biol. Med.(Maywood). 2008, 233, 549–557.